<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02624271</url>
  </required_header>
  <id_info>
    <org_study_id>RC14_0371</org_study_id>
    <nct_id>NCT02624271</nct_id>
  </id_info>
  <brief_title>Diagnosis of Gastric Precancerous Lesions by a Blood Test GastroPanel in Patients With Increased Gastric Cancer Risk</brief_title>
  <acronym>GASTRO-PRA</acronym>
  <official_title>Non Invasive Diagnosis of Gastric Precancerous Lesions by GastroPanel Blood Test in Patients With Increased Gastric Cancer Risk : a French Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the declining incidence, gastric cancer (GC) remains the second leading cause of
      cancer death worldwide. In France, it is the second digestive cancer with 7,000 new cases per
      year. It is now well demonstrated that patients with H. pylori infection, atrophic gastritis
      and intestinal metaplasia, have a high risk of developing GC. It is therefore important to
      detect these pre-neoplastic lesions at an early stage to improve patients prognosis.

      Thus, the aim of this project is to investigate the possible screening of gastric
      precancerous lesions by a blood test (GastroPanel®) in France, in patients with
      oesophagogastroduodenoscopy (EGD) prescription.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of GastroPanel blood test</measure>
    <time_frame>One assessment at baseline</time_frame>
    <description>The pepsinogen I (PGI) level measure will be compared with the gold standard method (anatomopathological examination of gastric biopsy). Results will be expressed in accordance with Sydney system. Patients will be classified as ill if PGI&lt;30µg/l, healthy if PGI &gt;=30µg/l. The sensitivity of GastroPanel test will be calculated with their 95% confidence interval.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Gastric Precancerous Lesions</condition>
  <arm_group>
    <arm_group_label>GastroPanel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GastroPanel test on blood samples</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood samples analysis</intervention_name>
    <description>Analyze blood samples with GastroPanel test to detect gastric precancerous lesions.</description>
    <arm_group_label>GastroPanel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing oesophagogastroduodenoscopy (EGD) according to usual care

          -  Patients with increased risk of gastric cancer (at least one of the following
             criteria):

               -  age &gt; 50 years,

               -  family cases of gastric cancer,

               -  known precancerous lesions,

               -  Biermer disease,

               -  H. Pylori infection,

               -  genetic predisposition (ex: Lynch syndrome),

               -  MALT lymphoma,

               -  dyspepsia.

          -  Subjects affiliated with an appropriate social security system

        Exclusion Criteria:

          -  Subjects with known active cancer

          -  Pregnancy

          -  Patients receiving proton-pump inhibitors

          -  Conditions that may interfere with the study objectives according to the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MATYSIAK BUDNIK Tamara, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MATYSIAK BUDNIK Tamara, Pr</last_name>
    <phone>02 40 08 31 51</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MATYSIAK BUDNIK Tamara, Pr</last_name>
      <phone>02 40 08 31 51</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2015</study_first_submitted>
  <study_first_submitted_qc>December 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2015</study_first_posted>
  <last_update_submitted>December 3, 2015</last_update_submitted>
  <last_update_submitted_qc>December 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>gastric precancerous lesions</keyword>
  <keyword>blood test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

